60 related articles for article (PubMed ID: 1603627)
1. Enzyme augmentation in moderate to life-threatening Gaucher disease.
Fallet S; Grace ME; Sibille A; Mendelson DS; Shapiro RS; Hermann G; Grabowski GA
Pediatr Res; 1992 May; 31(5):496-502. PubMed ID: 1603627
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
Abbas R; Park G; Damle B; Chertkoff R; Alon S
PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
[TBL] [Abstract][Full Text] [Related]
3. A case of bony lytic lesions in a patient with Gaucher disease.
McGinnis E; Moshref Razavi H
Clin Case Rep; 2019 Sep; 7(9):1685-1688. PubMed ID: 31534727
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma.
Shuai W; Wagner CE; Sukswai N; Medeiros LJ; Bueso-Ramos C; Oo TH
Clin Case Rep; 2019 Sep; 7(9):1804-1805. PubMed ID: 31534758
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease.
Lee FS; Yen HJ; Niu DM; Hung GY; Lee CY; Yeh YC; Chen PC; Chang SK; Yang CF
Mol Genet Metab Rep; 2020 Dec; 25():100652. PubMed ID: 33101978
[TBL] [Abstract][Full Text] [Related]
6. Ethical issues in managing Lysosomal storage disorders in children in low and middle income countries.
Afroze B; Brown N
Pak J Med Sci; 2017; 33(4):1036-1041. PubMed ID: 29067088
[TBL] [Abstract][Full Text] [Related]
7. Demographic Studies from a National Gaucher Disease Screening Program.
Gagnon DM; Pergament E; Fine BA
J Genet Couns; 1998 Oct; 7(5):385-99. PubMed ID: 26141627
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.
Sidransky E; Ginns EI
J Genet Couns; 1994 Mar; 3(1):13-22. PubMed ID: 24233795
[TBL] [Abstract][Full Text] [Related]
9. Imiglucerase in the treatment of Gaucher disease: a history and perspective.
Deegan PB; Cox TM
Drug Des Devel Ther; 2012; 6():81-106. PubMed ID: 22563238
[TBL] [Abstract][Full Text] [Related]
10. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.
Xu YH; Sun Y; Barnes S; Grabowski GA
PLoS One; 2010 May; 5(5):e10750. PubMed ID: 20505772
[TBL] [Abstract][Full Text] [Related]
11. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
Whittington R; Goa KL
Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294
[TBL] [Abstract][Full Text] [Related]
12. Alglucerase for Gaucher's disease: dose, costs and benefits.
Beutler E; Garber AM
Pharmacoeconomics; 1994 Jun; 5(6):453-9. PubMed ID: 10147261
[No Abstract] [Full Text] [Related]
13. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
MacKenzie JJ; Amato D; Clarke JT
CMAJ; 1998 Nov; 159(10):1273-8. PubMed ID: 9861225
[TBL] [Abstract][Full Text] [Related]
14. Oligosaccharide excretion in adult Gaucher disease.
de Jong JG; Aerts JM; van Weely S; Hollak CE; van Pelt J; van Woerkom LM; Liebrand-van Sambeek ML; Wevers RA
J Inherit Metab Dis; 1998 Feb; 21(1):49-59. PubMed ID: 9501269
[TBL] [Abstract][Full Text] [Related]
15. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages.
Beutler E; Kuhl W; Vaughan LM
Mol Med; 1995 Mar; 1(3):320-4. PubMed ID: 8529110
[TBL] [Abstract][Full Text] [Related]
16. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans.
Beutler E
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5384-90. PubMed ID: 8516282
[TBL] [Abstract][Full Text] [Related]
17. Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications.
Sibille A; Eng CM; Kim SJ; Pastores G; Grabowski GA
Am J Hum Genet; 1993 Jun; 52(6):1094-101. PubMed ID: 8503443
[TBL] [Abstract][Full Text] [Related]
18. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.
Sato Y; Beutler E
J Clin Invest; 1993 May; 91(5):1909-17. PubMed ID: 8486762
[TBL] [Abstract][Full Text] [Related]
19. Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.
Brady RO; Murray GJ; Barton NW
J Inherit Metab Dis; 1994; 17(4):510-9. PubMed ID: 7967500
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease: A G+1----A+1 IVS2 splice donor site mutation causing exon 2 skipping in the acid beta-glucosidase mRNA.
He GS; Grabowski GA
Am J Hum Genet; 1992 Oct; 51(4):810-20. PubMed ID: 1415223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
